PHAnews
vol 2, Number 16
August 3, 2001
PHAnews is a bi-weekly internet information resource for patients and caregivers. If you have suggested items for upcoming issues please send a brief description and web link to PHAnews editor, Sally Maddox skmaddox@bellsouth.net Welcome to this resource from PHA!
A list of topics for this issue are:
1) Doctors seek a Viagra variant for lung ailment
2) Mutation in the Gene for Bone Morphogenetic Protein Receptor II as a Cause of Primary Pulmonary Hypertension in a Large Kindred
3) United Therapeutics Announces Further Details Concerning FDA Advisory Committee Review of Remodulin for Pulmonary Arterial Hypertension
4) Critical Time for Drug Firm - FDA to Rule on Pulmonary-Hypertension Treatment
5) Cardiac Output -Ever wonder what those numbers really mean???
Doctors seek a Viagra variant for lung ailment
In 1998, cardiologists at Boston Children's Hospital were trying to keep alive a very sick baby girl whose lungs and heart were failing. But every time they tried to wean her from her ventilator and its accompanying medication, she relapsed. So they searched for another treatment and came up with one: Viagra, just on the market.
http://www.boston.com/dailyglobe2/215/nation/
Doctors_seek_a_Viagra_variant_for_lung_ailment+.shtml
Mutation in the Gene for Bone Morphogenetic Protein Receptor II as a Cause of Primary Pulmonary Hypertension in a Large Kindred
Most patients with primary pulmonary hypertension are thought to have sporadic, not inherited, disease. Because clinical disease develops in only 10 to 20 percent of persons carrying the gene for familial primary pulmonary hypertension, we hypothesized that many patients with apparently sporadic primary pulmonary hypertension may actually have familial primary pulmonary hypertension.
http://content.nejm.org/cgi/content/short/345/5/319
United Therapeutics Announces Further Details Concerning FDA Advisory Committee Review of Remodulin for Pulmonary Arterial Hypertension
Research Triangle Park, NC and Silver Spring, MD, July 29, 2001. United TherapeuticsCorporation (NASDAQ: UTHR) announced today that the Cardiovascular and RenalDrugs Advisory Committee review of Remodulin for Pulmonary Arterial Hypertension(PAH) would occur August 9, 2001, at 8:30 a.m. EDT at the National Institutes of Health,Jack Masur Auditorium, Building 10, 9000 Rockville Pike, Bethesda, Maryland.
http://www.unitedtherapeutics.com/pressReleases/07.29.01.pr.pdf
Critical Time for Drug Firm
FDA to Rule on Pulmonary-Hypertension Treatment
United officials, investors and patients anxiously await the Food and Drug Administration's decision on whether to approve Remodulin. Delayed twice since April, a decision is expected soon after the company meets with an FDA advisory panel on Aug. 9.
http://www.washingtonpost.com/wp-dyn/articles/A20018-2001Aug1.html
Cardiac Output -Ever wonder what those numbers really mean???
Explanation of Pulmonary artery systolic and diastolic pressure and mean pulmonary artery pressure.
www.mededcon.com/card01.htm
